Early Stage Science Watch
Scrip scans for early stage research – from bench to clinic – that could lead to novel treatments or changes in therapy recently published in major science journals.
You may also be interested in...
Hepatitis C is effectively cured. Could this success be replicated in another serious chronic viral condition ‒ HIV? Abivax, which last year abandoned its hepatitis B lead program, has bounced back with data suggesting a 'functional cure' for HIV is more than just a pipe dream.
An investigational hypolipemic product from Regeneron Pharmaceuticals with a novel mechanism of action appears to have great promise when used in addition to current therapies in familial hypercholesterolemia patients, suggest early data from a small study, but many questions remain.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.